|Hypertension||ACEI and ARBs first-line if BP >140/90 mm Hg61||Blocking RAS reduces hepatic fibrosis62 63|
|Escalate treatment according to NICE hypertension guidelines||ARBs improve transaminase levels and insulin sensitivity64|
|20% reduction in new onset T2DM with ACEI or ARBs65|
|Dyslipidaemia||Primary prevention with statin if ≥20% 10-year risk of developing cardiovascular disease66||Statins reduce 5-year incidence of all-cause mortality, major coronary events, coronary revascularisation and stroke by about 20% per mmol/L reduction in LDL cholesterol67|
|If secondary prevention, aim total cholesterol <4 mmol/L|
|May reduce incidence of HCC69|
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; HCC, hepatocellular carcinoma; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; T2DM, type 2 diabetes mellitus; RAS, renin–angiotensin system.